HYLEUKIN-7 - Trademark Details
Status: 606 - Abandoned - No Statement Of Use Filed
Image for trademark with serial number 88469477
Serial Number
88469477
Word Mark
HYLEUKIN-7
Status
606 - Abandoned - No Statement Of Use Filed
Status Date
2021-01-25
Filing Date
2019-06-12
Mark Drawing
4000 - Standard character mark Typeset
Published for Opposition Date
2020-04-28
Attorney Name
Law Office Assigned Location Code
N20
Employee Name
O'BRIEN, JENNIFER LYNN
Statements
Goods and Services
Antibiotics; Anti-cancer preparations; Anti-inflammatory preparations, namely, anti-inflammatory gels, ointments, salves, sprays, creams, pills, powders, granules, tablets, capsules, depots, suppository, syrup, tinctures and emulsion; Antiviral agent against human papilloma virus; Blood solvent for medical purposes, namely, blood plasma, albumin, globulin, fibrinogen, thrombocyte and platelets; Cardiovascular pharmaceutical preparations for the treatment and prevention of heart and vascular diseases; Dermatological pharmaceutical products; DNA vaccines; Drugs for medical purposes, namely, pharmaceutical drug preparations for the treatment and prevention of human papilloma virus infectious disease, cancer and cervical intraepithelial neoplasia; Injectable pharmaceuticals for medical purposes, namely, for the treatment and prevention of human papilloma virus infectious disease, cancer and cervical intraepithelial neoplasia; Medicines for sensory organs, namely, pharmaceutical preparations for the prevention, treatment, and cure of diseases and conditions impacting the eyes, ears, nose, mouth and nervous system; Pharmaceutical agents affecting digestive organs; Pharmaceutical agents affecting metabolism; Pharmaceutical preparations and compositions for the treatment and prevention of cancer; Pharmaceutical preparations for activating cellular function; Pharmaceutical preparations for anticancer immunotherapy; Pharmaceutical preparations for digestive organs, namely, for the prevention, treatment, and cure of diseases and conditions impacting digestive organs; Pharmaceutical preparations for gene therapy; Pharmaceutical preparations for immunomodulatory purposes, namely, for the regulation of immune functions; Pharmaceutical preparations for immunotherapy; Pharmaceutical preparations for preventing and treating obese; Pharmaceutical preparations for regulating the immune system; Pharmaceutical preparations for the prevention of osteoporosis; Pharmaceutical preparations for the treatment of autoimmune diseases; Pharmaceutical preparations for the treatment of cardiovascular disease; Pharmaceutical preparations for the treatment of cervical cancer; Pharmaceutical preparations for the treatment of cervical intraepithelial neoplasia; Pharmaceutical preparations for the treatment of cervical pre-cancer; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of head and neck cancer; Pharmaceutical preparations for the treatment of hormonal disorders; Pharmaceutical preparations for the treatment of multiple sclerosis; Pharmaceutical preparations for the treatment of osteoporosis; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for treating malignant tumours; Pharmaceutical preparations for urogenital organs; Pharmaceutical preparations for wounds; Pharmaceutical products and preparations, namely, for the treatment and prevention of human papilloma virus infectious disease, cancer and cervical intraepithelial neoplasia; Pharmaceutical products for the treatment of bone diseases; Pharmaceutical products for the treatment of cancer; Pharmaceutical products for the treatment of infectious diseases; Pharmaceutical products for the treatment of viral and infectious diseases; Pharmaceutical products for the treatment of viral diseases; Preventive vaccines; Preventive vaccines against human papilloma virus infections; Therapeutic vaccines; Vaccines; Pharmaceutical preparations for the treatment of lymphopenia; Immunoglobulin fusion protein pharmaceutical preparations, namely, antibodyfusion proteins for the treatment of cancer
Pseudo Mark
HYLEUKIN- SEVEN
Classification Information
International Class
005 - Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. - Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes
006, 018, 044, 046, 051, 052
Class Status Code
6 - Active
Class Status Date
2019-06-24
Primary Code
005
Correspondences
Name
James R Menker
Address
Please log in with your Justia account to see this address.
Trademark Events
Event DateEvent Description
2019-06-15NEW APPLICATION ENTERED IN TRAM
2019-06-24NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
2019-08-20ASSIGNED TO EXAMINER
2019-08-26NON-FINAL ACTION WRITTEN
2019-08-26NON-FINAL ACTION E-MAILED
2019-08-26NOTIFICATION OF NON-FINAL ACTION E-MAILED
2020-02-24TEAS RESPONSE TO OFFICE ACTION RECEIVED
2020-02-24CORRESPONDENCE RECEIVED IN LAW OFFICE
2020-02-24TEAS/EMAIL CORRESPONDENCE ENTERED
2020-02-24TEAS CHANGE OF OWNER ADDRESS RECEIVED
2020-02-24TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
2020-02-24ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
2020-02-24APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
2020-02-24TEAS CHANGE OF CORRESPONDENCE RECEIVED
2020-03-18EXAMINERS AMENDMENT -WRITTEN
2020-03-18EXAMINERS AMENDMENT E-MAILED
2020-03-18NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
2020-03-18EXAMINER'S AMENDMENT ENTERED
2020-03-19APPROVED FOR PUB - PRINCIPAL REGISTER
2020-03-25ASSIGNED TO LIE
2020-04-08NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
2020-04-28PUBLISHED FOR OPPOSITION
2020-04-28OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
2020-06-23NOA E-MAILED - SOU REQUIRED FROM APPLICANT
2021-01-25ABANDONMENT - NO USE STATEMENT FILED
2021-01-25ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED